All News
ACR 2022 - Day 1 Report
The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
Read Article
RA-ILD: an update
Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.
Read Article
The Great Debate! Should you treat pre-clinical RA?
ACPA+ ~40% did not convert to clinical RA
RF+/ACPA+ least likely to seroconvert to negative
@RheumNow #ACR22 https://t.co/djVPKDdWjz
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
US erosions in 5th MTPs predict clinical arthritis in +CCP "Pre-RA" patients
~15% of patients will develop RA
@RheumNow #ACR22 https://t.co/jS2YMlF4iO
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
"The more good factors you have, the less likely you will develop RA"
- Janet Pope
Never smoker, normal BMI, low EtOH, exercise, healthy diet
@RheumNow #ACR22 https://t.co/jIMOn8ht6u
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR22 The Great Debate: to treat subclinical #Rheumatoidarthritis or not. @Janetbirdope counted hands manually in person. Let's check out the #socialmedia community. What is your definition of sub-clinical RA? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Infections in pre-RA: a cause or a consequence?
Rheumatoid arthritis is known to be associated with a higher risk of infections, and this occurs for multiple reasons: immune dysfunction, systemic inflammation, comorbidities, and treatments.
https://t.co/N91Goop92l https://t.co/yvnRrsHSCB
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Michael Holers on preclinical RA
"Individuals who are anti-CCP positive are not clinically well. We just can't see what is going on"
@RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
First - likelihood of RA?
If you have +ACPA or RF in sputum, there is 67% chance of developing clinical RA!
@RheumNow #ACR22 https://t.co/K7pUhvbEDR
Robert B Chao, MD doctorRBC ( View Tweet)
The great debate
Next steps to develop RA prevention
Kevin Deane
“It’s time to move from disease modifying drugs to disease modifying therapeutic approaches”
#ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx
Aurelie Najm AurelieRheumo ( View Tweet)
Multiplex peripheral blood in 200+ ILD pts
Differences in IL-17 RD-ILD>IPF> IPAF
Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF
OR 0.4
Almost surprising considering known profibrotic role of IL-13 🧐
https://t.co/21UMq6w9hI
Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A
Aurelie Najm AurelieRheumo ( View Tweet)
There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID
David Liew drdavidliew ( View Tweet)
USA vs Canada
It's kicking off
and a super hot topic
The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis
Holers/Deane (treat 🇺🇸)
El Gabalawy/Pope (don't treat 🇨🇦)
What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf
David Liew drdavidliew ( View Tweet)
We know depression, anxiety are issues for many RA pts. Are we making the diagnosis more?
Olmsted County data:
depression similar over time
anxiety 3x more common in 2005-2014 vs 1985-1994 (adj age/sex +/- others)
How do we address this?
ABST0886 @MayoClinic #ACR22 @RheumNow https://t.co/tzMEE24FZo
David Liew drdavidliew ( View Tweet)
How to prescribe methotrexate in a post-Roe era:
Abstract #L09
💊 6% of > 1,700 patients reported access issues to MTX
-63% had a delay in filling script
🤰Excessive questions about possibility of pregnancy
🧑⚕️Pharmacy refused to fill
#ACR22 #ACRbest @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY
Richard Conway RichardPAConway ( View Tweet)
Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears to be an early factor in RA development
@RheumNow #ACR22 Abstr#0554 https://t.co/UL1jVGVlrA https://t.co/i1WWQlHs2m
Richard Conway RichardPAConway ( View Tweet)
Rech et al. 18 month results of ARIAA, 6 months abatacept in pre-RA, 1 year drug-free follow-up. 35% vs 65% developed RA. MRI response 57% vs 29%. @RheumNow #ACR22 Abstr#0530 https://t.co/35M2sPkIbW https://t.co/S8K39jkCh0
Richard Conway RichardPAConway ( View Tweet)
Schieir et al. Women with early RA less likely to achieve remission. 12 months 37% vs 43%. 4 years 61% vs 64%. Time to remission 19 months vs 16 months. @RheumNow #ACR22 Abstr#0532 https://t.co/ZRuqqaPHHU https://t.co/pDBHHtLEhs
Richard Conway RichardPAConway ( View Tweet)
Porter et al. Asymptomatic Pre-RA to symptomatic Pre-RA to early RA steady increase in bacterial infection compared to HC. Causality or Reverse Causality? I think more likely reverse - disease related immunosuppresion @RheumNow #ACR22 Abstr#0535 https://t.co/i5iN3Db7rf https://t.co/2ynYF7Vqbl
Richard Conway RichardPAConway ( View Tweet)
